ubt251 vs retatrutide at 24 week. • UBT251: up to 19.7% mean weight loss • Retatrutide: up to 17.5% Both are triple agonists targeting GLP-1, GIP & glucagon. Early Phase 2 data GLP-1-based therapies for diabetes, obesity

Glutathione (GSH) maintains a reduced cellular environment and is widely believed to mitigate disease-associated oxidative damage to proteins, thereby protecting against metabolic dysfunctionassociated steatotic liver disease (MASLD)

Los medicamentos aprobados por la FDA incluyen semaglutida (Ozempic para diabetes, Wegovy para control de peso), liraglutida (Victoza para diabetes, Saxenda para control de peso), dulaglutida (Trulicity para diabetes) y tirzepatida (Mounjaro para diabetes, Zepbound para control de peso), siendo esta ltima un agonista dual que acta sobre los receptores de GLP-1 y GIP

Pay Attention to What You Eat: Avoid acidic foods and beverages, minimize sugary snacks, and follow the GLP-1-recommended approach of eating smaller, more frequent meals, Tsang says

In people with lower starting weights, small doses could have big impacts, he says

T.AlzahraniM

I was concerned that starting tirzepatide would make things worse on that front